FDA Brief

Warning letters Drugs

FDA warning letter to

Novo Nordisk Inc.

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.

What happened

FDA reviewed a 42-minute direct-to-consumer video, “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” about Wegovy, Ozempic, and Victoza. The video aired on ABC on March 18, 2024, later appeared on Hulu, and featured Novo Nordisk paid consultants and a sales executive. FDA found the video false or misleading because it omitted and downplayed serious risks, including a highlighted serious-risk warning, and because the promotional materials were not submitted when first published.

What FDA found

  1. The video left out the boxed warning’s rule that people with a personal or family history of MEN 2, a rare endocrine condition, should not use these drugs because of thyroid cancer risk.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5); (e)(7)(viii)
  2. The video omitted other serious risks listed in the label, including low blood sugar, acute kidney injury, allergic reactions, diabetic eye problems, increased heart rate, suicidal thoughts or behavior, and sharing a pen between patients.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5); (e)(7)(viii)
  3. A paid consultant called pancreatitis, gallbladder complications, and thyroid cancer concerns “hype” and “very, very rare,” which FDA says wrongly minimized serious risks.

    21 U.S.C. 352(a); 21 CFR 202.1(e)(5)
  4. A paid consultant said GLP-1 side effects were “overhyped” and “mild to moderate,” even though the label reports severe gastrointestinal reactions and discontinuations in trials.

    21 CFR 202.1(e)(5); (e)(7)(viii)
  5. Novo Nordisk did not submit the promotional materials when they were first published, as required.

    21 CFR 314.81(b)(3)(i)

What FDA wants

FDA says distribution of the video violates the law and calls for truthful, nonmisleading promotion of these drugs. The provided text does not state a response deadline.

Who should pay attention

  • drugmakers that promote GLP-1 medicines
  • medical and promotional review teams
  • clinicians and patients choosing obesity or diabetes treatment

This is a summary. Read the original letter on fda.gov.

Novo Nordisk Inc.'s FDA history

  1. Novo Nordisk Inc.

    FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.

    High risk

Recalls in the last 12 months

Jan 7 Class II Novo Nordisk Inc.
Drug
Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC…
Presence of Particulate Matter: Hair was found in a prefilled syringe
Jan 7 Class II Novo Nordisk Inc.
Drug
Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, N…
Presence of Particulate Matter: Hair was found in a prefilled syringe

Full company page

Similar letters to other companies

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  3. Herbal Dermals LLC FZ dba Gotucream

    FDA warned Herbal Dermals LLC FZ dba Gotucream that its Gotucream balanitis cream is an unapproved new drug.

    Low
  4. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low